These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 6943974)

  • 1. Structural studies on a biologically active hexasaccharide obtained from heparin.
    Choay J; Lormeau JC; Petitou M; Sinaÿ P; Fareed J
    Ann N Y Acad Sci; 1981; 370():644-9. PubMed ID: 6943974
    [No Abstract]   [Full Text] [Related]  

  • 2. An investigation of the functional role of the carboxylic groups of heparin. Affinity for antithrombin III and anti-Xa activity of selectively carboxyl esterified heparin.
    Mardiguian J; Trillou M
    Semin Thromb Hemost; 1985 Jan; 11(1):34-6. PubMed ID: 3975640
    [No Abstract]   [Full Text] [Related]  

  • 3. Preliminary biochemical and pharmacologic studies on a chemically synthesized pentasaccharide.
    Walenga JM; Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):89-99. PubMed ID: 4035370
    [No Abstract]   [Full Text] [Related]  

  • 4. Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments.
    Racanelli A; Fareed J; Walenga JM; Coyne E
    Semin Thromb Hemost; 1985 Apr; 11(2):176-89. PubMed ID: 4035365
    [No Abstract]   [Full Text] [Related]  

  • 5. From heparin to heparin fractions and derivatives.
    Coyne E
    Semin Thromb Hemost; 1985 Jan; 11(1):10-2. PubMed ID: 3883496
    [No Abstract]   [Full Text] [Related]  

  • 6. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies.
    Casu B; Oreste P; Torri G; Zoppetti G; Choay J; Lormeau JC; Petitou M; Sinäy P
    Biochem J; 1981 Sep; 197(3):599-609. PubMed ID: 7325974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate.
    Ofosu FA; Fernandez F; Gauthier D; Buchanan MR
    Semin Thromb Hemost; 1985 Apr; 11(2):133-7. PubMed ID: 3898370
    [No Abstract]   [Full Text] [Related]  

  • 8. Distribution of glucuronic and iduronic acid units in heparin chains.
    Radoff S; Danishefsky I
    J Biol Chem; 1985 Dec; 260(28):15106-11. PubMed ID: 4066664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Location on heparin of the oligosaccharide section essential for anticoagulant activity.
    Radoff S; Danishefsky I
    J Biol Chem; 1984 Jan; 259(1):166-72. PubMed ID: 6706928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Low molecular weight oligosaccharides active in plasma against factor Xa. II. New structural elements and antithrombotic activity (author's transl)].
    Choay J; Lormeau JC; Petitou M; Fareed J; Sinaÿ P
    Ann Pharm Fr; 1981 Jul; 39(3):267-72. PubMed ID: 7294654
    [No Abstract]   [Full Text] [Related]  

  • 11. Antithrombotic effects of heparin oligosaccharides.
    Mattsson C; Palm M; Söderberg K; Holmer E
    Ann N Y Acad Sci; 1989; 556():323-32. PubMed ID: 2735663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
    Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Low molecular weight oligosaccharides active in plasma against factor Xa (author's transl)].
    Choay J; Lormeau JC; Petitou M
    Ann Pharm Fr; 1981 May; 39(1):37-44. PubMed ID: 7247232
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of Ca2+, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affinity oligosaccharides.
    Barrowcliffe TW; Havercroft SJ; Kemball-Cook G; Lindahl U
    Biochem J; 1987 Apr; 243(1):31-7. PubMed ID: 3606581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term intraperitoneal application of low molecular weight heparin in a continuous ambulatory peritoneal dialysis patient with deep vein thrombosis.
    Schrader J; Tönnis HJ; Scheler F
    Nephron; 1986; 42(1):83-4. PubMed ID: 3941753
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization of a new potent heparin. 2nd communication: Chemical analysis of the carbohydrate content and determination of the biological activity of a new potent heparin preparation in vitro, using protamine neutralization and amidolytic methods for factor Xa and thrombin.
    Bhargava AS; Heinick J; Günzel P
    Arzneimittelforschung; 1980; 30(7):1071-4. PubMed ID: 7191289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of heparin cofactor II by heparin oligosaccharides.
    Maimone MM; Tollefsen DM
    Biochem Biophys Res Commun; 1988 May; 152(3):1056-61. PubMed ID: 3377765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation.
    Massonnet-Castel S; Pelissier E; Bara L; Terrier E; Abry B; Guibourt P; Swanson J; Jaulmes B; Carpentier A; Samama M
    Haemostasis; 1986; 16(2):139-46. PubMed ID: 3710291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic studies on chemically synthesized pentasaccharide and tetrasaccharide fragments.
    Choay J
    Semin Thromb Hemost; 1985 Apr; 11(2):81-5. PubMed ID: 4035368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions.
    Fareed J; Kumar A; Rock A; Walenga JM; Davis P
    Semin Thromb Hemost; 1985 Apr; 11(2):138-54. PubMed ID: 4035364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.